Freshpet's 
FRPT future growth looks very good based on *current* estimates. The company's revenue is anticipated to grow from $1.18B–$1.21B in 2025 to ~$1.9B by 2028, implying an annual growth rate of ~13–17%. FRPT targets a 22% adjusted EBITDA margin by 2027, with adjusted EBITDA expected at $190M–$210M in 2025. The stock is definitely not "cheap" right now with a price-to-earnings of 92x. However, the growth projections look solid if they can maintain the pace of growth through a tumultuous economy - the pet market is wildly resilient.
Since February 2025, insiders have grabbed over $931,764 in shares at an average price of $100.93. The only open price gap below the current price was a closed yesterday. A blaring price gap between $124-$128 is likely to be closed - just a matter of when. With very low debt (debt-to-earnings of 0.5x), Quick Ratio over 3 (heathy), and Altman's Z-score of 3+ (low bankruptcy risk), the company appears extremely healthy. I think there is a chance the price could reach into the high $40's and $50's in the near-term, but long term... if the projections are correct... the company looks poised from major profit.
Thus, at $63.15,FRPT is in a personal buy zone with near-term risk of a drop into the high $40s and $50s.
Targets into 2028:
FRPT future growth looks very good based on *current* estimates. The company's revenue is anticipated to grow from $1.18B–$1.21B in 2025 to ~$1.9B by 2028, implying an annual growth rate of ~13–17%. FRPT targets a 22% adjusted EBITDA margin by 2027, with adjusted EBITDA expected at $190M–$210M in 2025. The stock is definitely not "cheap" right now with a price-to-earnings of 92x. However, the growth projections look solid if they can maintain the pace of growth through a tumultuous economy - the pet market is wildly resilient.Since February 2025, insiders have grabbed over $931,764 in shares at an average price of $100.93. The only open price gap below the current price was a closed yesterday. A blaring price gap between $124-$128 is likely to be closed - just a matter of when. With very low debt (debt-to-earnings of 0.5x), Quick Ratio over 3 (heathy), and Altman's Z-score of 3+ (low bankruptcy risk), the company appears extremely healthy. I think there is a chance the price could reach into the high $40's and $50's in the near-term, but long term... if the projections are correct... the company looks poised from major profit.
Thus, at $63.15,
FRPT is in a personal buy zone with near-term risk of a drop into the high $40s and $50s.Targets into 2028:
- $90.00 (+42.5%)
- $125.00 (+ 97.9%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.